Pub Date : 2026-03-09DOI: 10.1016/s1473-3099(26)00001-0
Lalita Priyamvada PhD, Faisal S Minhaj PharmD, Toutou Likafi MScN, Elisabeth Pukuta MSc, Elisabeth Muyamuna BSc, William C Carson BSc, Margaret Moriarty BSc, Sergio Rodriguez PhD, Taina Joseph MPH, Joelle Kabamba MD, Gaston Kokola BSc, Robert Shongo Lushima MD, Jean-Jacques Muyembe-Tamfum MD, Christine M Hughes MPH, Brett W Petersen MD, Yon Yu PharmD, Agam Rao MD, Andrea M McCollum PhD, Prof Didine K Kaba MD, Beatrice U Nguete MD, Panayampalli S Satheshkumar PhD, Michael B Townsend PhD
The expanding mpox outbreak in Africa and travel-associated cases in other continents have increased efforts to vaccinate populations at high risk. This study aimed to assess serological immune responses 5 years after individuals received a primary vaccination (two-dose series) with the smallpox and mpox vaccine modified vaccinia Ankara-Bavarian Nordic (MVA-BN), as well as to evaluate the safety and immunogenicity of a third dose (booster). To date, there are no data for immunological memory or third-dose-induced immunity for MVA-BN at these long-term timescales.
{"title":"Immunogenicity and safety of MVA-BN vaccine administered 5 years after a two-dose primary series in DR Congo: a prospective cohort study","authors":"Lalita Priyamvada PhD, Faisal S Minhaj PharmD, Toutou Likafi MScN, Elisabeth Pukuta MSc, Elisabeth Muyamuna BSc, William C Carson BSc, Margaret Moriarty BSc, Sergio Rodriguez PhD, Taina Joseph MPH, Joelle Kabamba MD, Gaston Kokola BSc, Robert Shongo Lushima MD, Jean-Jacques Muyembe-Tamfum MD, Christine M Hughes MPH, Brett W Petersen MD, Yon Yu PharmD, Agam Rao MD, Andrea M McCollum PhD, Prof Didine K Kaba MD, Beatrice U Nguete MD, Panayampalli S Satheshkumar PhD, Michael B Townsend PhD","doi":"10.1016/s1473-3099(26)00001-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(26)00001-0","url":null,"abstract":"The expanding mpox outbreak in Africa and travel-associated cases in other continents have increased efforts to vaccinate populations at high risk. This study aimed to assess serological immune responses 5 years after individuals received a primary vaccination (two-dose series) with the smallpox and mpox vaccine modified vaccinia Ankara-Bavarian Nordic (MVA-BN), as well as to evaluate the safety and immunogenicity of a third dose (booster). To date, there are no data for immunological memory or third-dose-induced immunity for MVA-BN at these long-term timescales.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"15 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147392879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-09DOI: 10.1016/s1473-3099(26)00051-4
Luis Flores Girón MSc, Gustavo Sganzerla Martinez PhD, Baganda Ntahuma Daniel MD, Alfred Kesheni Bisimwa MD, Nkonzi Pacific MD, Georges Assumani Martin BVSc, Jean Christian Amini Kabwana BSc, Anuj Kumar PhD, Ali Toloue Ostadgavahi MSc, Mansi Dutt MSc, Kawaya Lusante Bénite BSc, Mangura Hamuli Damien BSc, Prof Christian Gortázar PhD, Bahaa Abu-Raya PhD, Alyson A Kelvin PhD, Kaleme Kiswele Prince PhD, Prof David J Kelvin PhD
Mpox is a public health concern in eastern DR Congo. It continues to cause substantial numbers of hospital admissions, with changing demographics including children and adolescents, requiring comprehensive clinical and epidemiological investigation. In this study, we aim to describe the clinical characteristics of hospitalised participants infected with monkeypox virus (MPXV) subclade Ib/2023sh in the Kabare Territory in South Kivu, DR Congo.
{"title":"Case presentation of patients hospitalised with mpox (subclade Ib/2023sh) including children, adolescents, and adults in South Kivu, Democratic Republic of the Congo: an observational cohort study","authors":"Luis Flores Girón MSc, Gustavo Sganzerla Martinez PhD, Baganda Ntahuma Daniel MD, Alfred Kesheni Bisimwa MD, Nkonzi Pacific MD, Georges Assumani Martin BVSc, Jean Christian Amini Kabwana BSc, Anuj Kumar PhD, Ali Toloue Ostadgavahi MSc, Mansi Dutt MSc, Kawaya Lusante Bénite BSc, Mangura Hamuli Damien BSc, Prof Christian Gortázar PhD, Bahaa Abu-Raya PhD, Alyson A Kelvin PhD, Kaleme Kiswele Prince PhD, Prof David J Kelvin PhD","doi":"10.1016/s1473-3099(26)00051-4","DOIUrl":"https://doi.org/10.1016/s1473-3099(26)00051-4","url":null,"abstract":"Mpox is a public health concern in eastern DR Congo. It continues to cause substantial numbers of hospital admissions, with changing demographics including children and adolescents, requiring comprehensive clinical and epidemiological investigation. In this study, we aim to describe the clinical characteristics of hospitalised participants infected with monkeypox virus (MPXV) subclade Ib/2023sh in the Kabare Territory in South Kivu, DR Congo.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"17 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147392877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-09DOI: 10.1016/s1473-3099(26)00006-x
Jenny Clarke, Herve Semukunzi, Sian E Faustini, Jennifer L J Heaney, Hin Fai Kwok, Jean Marie Vianney Uwimana, Karishma Gokani, Gilbert Rukundo, Jean Pierre Musabyimana, Prosper Ingabire, Leopold Bitunguhari, Jean de Dieu Harelimana, Alex G Richter, Claude M Muvunyi, Christopher A Green
<h3>Background</h3>Validated serological assays for mpox are scarce, particularly in outbreak regions where they are most urgently needed. We aimed to conduct an in-country validation of a serum-based mpox IgG ELISA during an outbreak of clade Ib mpox in Rwanda, and report immunological observations after infection and vaccination and on background seropositivity.<h3>Methods</h3>This observational, cross-sectional, clinical validation study of an mpox-specific IgG ELISA was conducted at the Rwanda National Reference Laboratory, within the Rwanda Biomedical Centre, Kigali, Rwanda. Adults (aged ≥18 years) were recruited into one of three groups of equal size: those who had previously had a microbiologically confirmed mpox infection (the infection cohort), those who had previously received an mpox vaccination (the vaccination cohort), and individuals with no history of mpox infection or vaccination (the unexposed cohort). Venous blood and dried blood spot (DBS) samples were collected from the participants. The IgG assay, containing four immunodominant mpox antigens, was developed into plate-based ELISA kits and used to analyse the serum and DBS samples, and an IgG ratio was obtained from the optical density readout. The performance of the assay was assessed by analysis of the receiver operating characteristic curve, intra-assay and interassay precision, and linearity, and the agreement between serum and DBS concentrations was tested with Spearman's correlation and Bland–Altman analysis.<h3>Findings</h3>Between Aug 1 and Aug 12, 2025, 194 individuals were invited to participate in the study, of whom 150 were enrolled, 50 in each of the three cohorts. Median IgG ratios were 3·24 (IQR 1·33–8·01) in the infection cohort, 1·77 (0·90–2·86) in the vaccination cohort, and 0·68 (0·39–1·16) in the unexposed cohort. IgG ratios in the infection and vaccination cohorts overlapped, but were both significantly higher than in the unexposed cohort (p<0·0001 for the infection cohort; p=0·0002 for the vaccination cohort). Intra-assay (coefficient of variation ≤13%) and interassay (≤10%) precision was high, and ratios were linear across dilutions. DBS and serum measurements were strongly correlated (<em>R</em><sup>2</sup>=0·84), but DBS measurements showed a small underestimation. In the vaccination cohort, IgG ratios were higher in female participants (median 2·70 [IQR 0·83–3·77], n=21) than in male participants (1·35 [0·90–2·42], n=29; p=0·0030).<h3>Interpretation</h3>We show that an mpox ELISA can be implemented within a national reference laboratory in a resource-limited setting as part of outbreak-response measures. The assay is suitable for population-level surveys and can analyse both DBS and serum samples. These findings provide a platform for larger population studies and further work to explore immune correlates of protection in mpox.<h3>Funding</h3>United Nations Environment Programme and the UK Department for Environment, Food and Rural Affairs; East Afr
{"title":"A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation study","authors":"Jenny Clarke, Herve Semukunzi, Sian E Faustini, Jennifer L J Heaney, Hin Fai Kwok, Jean Marie Vianney Uwimana, Karishma Gokani, Gilbert Rukundo, Jean Pierre Musabyimana, Prosper Ingabire, Leopold Bitunguhari, Jean de Dieu Harelimana, Alex G Richter, Claude M Muvunyi, Christopher A Green","doi":"10.1016/s1473-3099(26)00006-x","DOIUrl":"https://doi.org/10.1016/s1473-3099(26)00006-x","url":null,"abstract":"<h3>Background</h3>Validated serological assays for mpox are scarce, particularly in outbreak regions where they are most urgently needed. We aimed to conduct an in-country validation of a serum-based mpox IgG ELISA during an outbreak of clade Ib mpox in Rwanda, and report immunological observations after infection and vaccination and on background seropositivity.<h3>Methods</h3>This observational, cross-sectional, clinical validation study of an mpox-specific IgG ELISA was conducted at the Rwanda National Reference Laboratory, within the Rwanda Biomedical Centre, Kigali, Rwanda. Adults (aged ≥18 years) were recruited into one of three groups of equal size: those who had previously had a microbiologically confirmed mpox infection (the infection cohort), those who had previously received an mpox vaccination (the vaccination cohort), and individuals with no history of mpox infection or vaccination (the unexposed cohort). Venous blood and dried blood spot (DBS) samples were collected from the participants. The IgG assay, containing four immunodominant mpox antigens, was developed into plate-based ELISA kits and used to analyse the serum and DBS samples, and an IgG ratio was obtained from the optical density readout. The performance of the assay was assessed by analysis of the receiver operating characteristic curve, intra-assay and interassay precision, and linearity, and the agreement between serum and DBS concentrations was tested with Spearman's correlation and Bland–Altman analysis.<h3>Findings</h3>Between Aug 1 and Aug 12, 2025, 194 individuals were invited to participate in the study, of whom 150 were enrolled, 50 in each of the three cohorts. Median IgG ratios were 3·24 (IQR 1·33–8·01) in the infection cohort, 1·77 (0·90–2·86) in the vaccination cohort, and 0·68 (0·39–1·16) in the unexposed cohort. IgG ratios in the infection and vaccination cohorts overlapped, but were both significantly higher than in the unexposed cohort (p<0·0001 for the infection cohort; p=0·0002 for the vaccination cohort). Intra-assay (coefficient of variation ≤13%) and interassay (≤10%) precision was high, and ratios were linear across dilutions. DBS and serum measurements were strongly correlated (<em>R</em><sup>2</sup>=0·84), but DBS measurements showed a small underestimation. In the vaccination cohort, IgG ratios were higher in female participants (median 2·70 [IQR 0·83–3·77], n=21) than in male participants (1·35 [0·90–2·42], n=29; p=0·0030).<h3>Interpretation</h3>We show that an mpox ELISA can be implemented within a national reference laboratory in a resource-limited setting as part of outbreak-response measures. The assay is suitable for population-level surveys and can analyse both DBS and serum samples. These findings provide a platform for larger population studies and further work to explore immune correlates of protection in mpox.<h3>Funding</h3>United Nations Environment Programme and the UK Department for Environment, Food and Rural Affairs; East Afr","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"6 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147384142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-09DOI: 10.1016/s1473-3099(26)00121-0
Yap Boum, Mosoka Fallah, Michel Muteba, Henry Kyobe Bosa, Kyeng Mercy, John Misaki Wayengera, Bruce Kirenga, John Otshudiema, Placide Mbala, Marie-Roseline Belizaire, Ngashi Ngongo, Jean Kaseya
{"title":"From emergency to integration: research as the bridge in mpox control","authors":"Yap Boum, Mosoka Fallah, Michel Muteba, Henry Kyobe Bosa, Kyeng Mercy, John Misaki Wayengera, Bruce Kirenga, John Otshudiema, Placide Mbala, Marie-Roseline Belizaire, Ngashi Ngongo, Jean Kaseya","doi":"10.1016/s1473-3099(26)00121-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(26)00121-0","url":null,"abstract":"","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"26 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147392878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-09DOI: 10.1016/s1473-3099(25)00779-0
Faisal S Minhaj, Anna Mandra, Béatrice U Nguete, Toutou Likafi, Gaston Kokola, Stephanie Tran, Jordan L Kennedy, Benjamin Monroe, Christine M Hughes, Taina Joseph, Marissa K Person, Michael B Townsend, Panayampalli S Satheshkumar, Joelle Kabamba, Mary G Reynolds, Agam K Rao, Dorah Kasongo, Patricia A Yu, Yon Yu, Robert Shongo Lushima, Andrea M McCollum
<h3>Background</h3>Modified vaccinia Ankara-Bavarian Nordic (MVA-BN) is a third-generation, replication-deficient, smallpox and mpox vaccine that is prepared in liquid and lyophilised formulations. DR Congo reports the highest number of mpox cases annually. Safety data on MVA-BN are available from high-income countries, but comprehensive safety evaluations of MVA-BN are limited in the African continent.<h3>Methods</h3>From Feb 23 to Aug 29, 2017, and from Aug 15 to Sept 17, 2019, 1600 adult (aged 18 years and older) health-care personnel (eg, physicians, nurses, and technicians) at risk for mpox in the Tshuapa province and in Kinshasa were enrolled in an investigational prospective cohort study to evaluate safety of the two-dose MVA-BN vaccine series. Participants were excluded if they were pregnant, acutely ill, involved in another research study or had vaccine administration in the past 28 days, or had conditions that could have put the participant at an unacceptable risk. 1000 (62·5%) participants were administered the liquid formulation and 600 (37·5%) participants were administered the reconstituted lyophilised formulation. Vaccine doses were given on study days 0 and 28 and participants followed up at specified timepoints for up to 2 years for serological monitoring (14, 28, 42, 180, 365, 545, and 730 days). Participants were evaluated for immediate vaccine reactions, given adverse event diaries to document specific adverse events for 7 days following vaccine administration, and asked about potential adverse events at later timepoints up to the 2-year mark. The primary outcome was to assess the safety of MVA-BN for up to 2 years across formulations in a population at increased risk of mpox. This study is registered with <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span> (<span><span>NCT02977715</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>).<h3>Findings</h3>There was no significant difference in the risk of an adverse event between the liquid formulation (488 [49·0%] of 995 participants) and lyophilised formulation (315 [53·7%] of 586 participants; adjusted risk ratio [aRR] 1·08 [95% CI 0·98–1·19]) within 7 days after vaccination. Within 7 days of vaccine administration, participants had similar proportions of local injection-site reactions between the liquid (356 [35·7%] of 995 participants) and lyophilised (213 [36·3%] of 586 participants) formulations, but those who received the lyophilised formulation had a higher risk for systemic symptoms than those who received the liquid formulation (aRR 1·20 [95% CI 1·05–1·37]). 18 serious adverse events, including 17 deaths and one stillbirth, oc
{"title":"Safety of MVA-BN vaccine in health-care personnel in DR Congo: a prospective cohort study","authors":"Faisal S Minhaj, Anna Mandra, Béatrice U Nguete, Toutou Likafi, Gaston Kokola, Stephanie Tran, Jordan L Kennedy, Benjamin Monroe, Christine M Hughes, Taina Joseph, Marissa K Person, Michael B Townsend, Panayampalli S Satheshkumar, Joelle Kabamba, Mary G Reynolds, Agam K Rao, Dorah Kasongo, Patricia A Yu, Yon Yu, Robert Shongo Lushima, Andrea M McCollum","doi":"10.1016/s1473-3099(25)00779-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00779-0","url":null,"abstract":"<h3>Background</h3>Modified vaccinia Ankara-Bavarian Nordic (MVA-BN) is a third-generation, replication-deficient, smallpox and mpox vaccine that is prepared in liquid and lyophilised formulations. DR Congo reports the highest number of mpox cases annually. Safety data on MVA-BN are available from high-income countries, but comprehensive safety evaluations of MVA-BN are limited in the African continent.<h3>Methods</h3>From Feb 23 to Aug 29, 2017, and from Aug 15 to Sept 17, 2019, 1600 adult (aged 18 years and older) health-care personnel (eg, physicians, nurses, and technicians) at risk for mpox in the Tshuapa province and in Kinshasa were enrolled in an investigational prospective cohort study to evaluate safety of the two-dose MVA-BN vaccine series. Participants were excluded if they were pregnant, acutely ill, involved in another research study or had vaccine administration in the past 28 days, or had conditions that could have put the participant at an unacceptable risk. 1000 (62·5%) participants were administered the liquid formulation and 600 (37·5%) participants were administered the reconstituted lyophilised formulation. Vaccine doses were given on study days 0 and 28 and participants followed up at specified timepoints for up to 2 years for serological monitoring (14, 28, 42, 180, 365, 545, and 730 days). Participants were evaluated for immediate vaccine reactions, given adverse event diaries to document specific adverse events for 7 days following vaccine administration, and asked about potential adverse events at later timepoints up to the 2-year mark. The primary outcome was to assess the safety of MVA-BN for up to 2 years across formulations in a population at increased risk of mpox. This study is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT02977715</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>).<h3>Findings</h3>There was no significant difference in the risk of an adverse event between the liquid formulation (488 [49·0%] of 995 participants) and lyophilised formulation (315 [53·7%] of 586 participants; adjusted risk ratio [aRR] 1·08 [95% CI 0·98–1·19]) within 7 days after vaccination. Within 7 days of vaccine administration, participants had similar proportions of local injection-site reactions between the liquid (356 [35·7%] of 995 participants) and lyophilised (213 [36·3%] of 586 participants) formulations, but those who received the lyophilised formulation had a higher risk for systemic symptoms than those who received the liquid formulation (aRR 1·20 [95% CI 1·05–1·37]). 18 serious adverse events, including 17 deaths and one stillbirth, oc","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"71 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147384095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-02DOI: 10.1016/s1473-3099(26)00120-9
{"title":"Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9","authors":"","doi":"10.1016/s1473-3099(26)00120-9","DOIUrl":"https://doi.org/10.1016/s1473-3099(26)00120-9","url":null,"abstract":"","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"31 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147360569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-01-08DOI: 10.1016/S1473-3099(25)00776-5
Bingyu Zhang, Qiong Wu, Ravi Jhaveri, Christopher B Forrest, Yong Chen
{"title":"Methodological considerations in the attribution of long COVID to first or second infection - Authors' reply.","authors":"Bingyu Zhang, Qiong Wu, Ravi Jhaveri, Christopher B Forrest, Yong Chen","doi":"10.1016/S1473-3099(25)00776-5","DOIUrl":"10.1016/S1473-3099(25)00776-5","url":null,"abstract":"","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":" ","pages":"e141"},"PeriodicalIF":31.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01DOI: 10.1016/S1473-3099(26)00009-5
David L Paterson, Abdullah T Aslan, Patrick N A Harris
{"title":"Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance - Authors' reply.","authors":"David L Paterson, Abdullah T Aslan, Patrick N A Harris","doi":"10.1016/S1473-3099(26)00009-5","DOIUrl":"https://doi.org/10.1016/S1473-3099(26)00009-5","url":null,"abstract":"","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"26 3","pages":"e145"},"PeriodicalIF":31.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147318915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01DOI: 10.1016/S1473-3099(26)00008-3
Brenda A Warecki, María F Mojica, Alejandro J Vila, Robert A Bonomo
{"title":"Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance.","authors":"Brenda A Warecki, María F Mojica, Alejandro J Vila, Robert A Bonomo","doi":"10.1016/S1473-3099(26)00008-3","DOIUrl":"https://doi.org/10.1016/S1473-3099(26)00008-3","url":null,"abstract":"","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"26 3","pages":"e144"},"PeriodicalIF":31.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147318841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01DOI: 10.1016/S1473-3099(26)00079-4
Ursula Hofer
{"title":"Peer review at The Lancet Infectious Diseases in 2025.","authors":"Ursula Hofer","doi":"10.1016/S1473-3099(26)00079-4","DOIUrl":"https://doi.org/10.1016/S1473-3099(26)00079-4","url":null,"abstract":"","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"26 3","pages":"223"},"PeriodicalIF":31.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147318843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：